Malignant neoplasm of prostate C61-

Use Additional
Use Additional Help
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation. In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere." Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code. "In diseases classified elsewhere" codes are never permitted to be used as first listed or principle diagnosis codes. They must be used in conjunction with an underlying condition code and they must be listed following the underlying condition.
  • code to identify:
  • hormone sensitivity status (
    ICD-10-CM Diagnosis Code Z19.1

    Hormone sensitive malignancy status

      2017 - New Code 2018 2019 2020 2021 Billable/Specific Code POA Exempt
    ICD-10-CM Diagnosis Code Z19.2

    Hormone resistant malignancy status

      2017 - New Code 2018 2019 2020 2021 Billable/Specific Code POA Exempt
    Applicable To
    • Castrate resistant prostate malignancy status
  • rising PSA following treatment for malignant neoplasm of prostate (
    ICD-10-CM Diagnosis Code R97.21

    Rising PSA following treatment for malignant neoplasm of prostate

      2017 - New Code 2018 2019 2020 2021 Billable/Specific Code Adult Dx (15-124 years) Male Dx Questionable As Admission Dx
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C61. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • malignant neoplasm of seminal vesicle (
    ICD-10-CM Diagnosis Code C63.7

    Malignant neoplasm of other specified male genital organs

      2016 2017 2018 2019 2020 2021 Billable/Specific Code Male Dx
    Applicable To
    • Malignant neoplasm of seminal vesicle
    • Malignant neoplasm of tunica vaginalis
Clinical Information
  • A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.
  • The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, being african-american, and some genetic changes.symptoms of prostate cancer may include
    • problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling
    • low back pain
    • pain with ejaculation
    your doctor will diagnose prostate cancer by feeling the prostate through the wall of the rectum or doing a blood test for prostate-specific antigen (psa). Other tests include ultrasound, x-rays, or a biopsy.treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. nih: national cancer institute
  • C61 Malignant neoplasm of prostate